{"id":"metoclopramide-and-ondanteron","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Tardive dyskinesia (metoclopramide)"}]},"_chembl":{"chemblId":"CHEMBL1200940","moleculeType":"Small molecule","molecularWeight":"354.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metoclopramide acts as a dopamine antagonist that increases gastric contractions and accelerates gastric emptying, while ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Together, they provide complementary antiemetic and prokinetic effects for managing nausea, vomiting, and gastric dysmotility.","oneSentence":"This combination blocks dopamine receptors (metoclopramide) to enhance gastric motility and blocks serotonin 5-HT3 receptors (ondansetron) to prevent nausea and vomiting.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:08.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nausea and vomiting (likely postoperative or chemotherapy-induced)"},{"name":"Gastric dysmotility and delayed gastric emptying"}]},"trialDetails":[{"nctId":"NCT05087615","phase":"PHASE3","title":"Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-03-01","conditions":"Bariatric Surgery Candidate, Perioperative Complication, Nausea","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metoclopramide and Ondanteron","genericName":"Metoclopramide and Ondanteron","companyName":"Shahid Beheshti University of Medical Sciences","companyId":"shahid-beheshti-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks dopamine receptors (metoclopramide) to enhance gastric motility and blocks serotonin 5-HT3 receptors (ondansetron) to prevent nausea and vomiting. Used for Nausea and vomiting (likely postoperative or chemotherapy-induced), Gastric dysmotility and delayed gastric emptying.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}